Evidence map›Paper›PMID 42540407›Full record

ArticleBJUI compass2026

Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma.

Sakari Kosola, Teemu D Laajala, Iida Payne, Antti Kukkula, Lassi Luomala, Tuomas Mirtti, Kalle Mattila, Paula Vainio, Maria Sundvall, Panu M Jaakkola

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sakari KosolaDepartment of Oncology and Radiotherapy, FICAN West Cancer Centre University of Turku and Turku University Hospital Turku Finland.ORCID https://orcid.org/0009-0001-3959-0736
Teemu D LaajalaDepartment of Mathematics and Statistics University of Turku Turku Finland.
Iida PayneCancer Research Unit, Institute of Biomedicine and FICAN West Cancer Research Laboratories University of Turku Turku Finland.
Antti KukkulaCancer Research Unit, Institute of Biomedicine and FICAN West Cancer Research Laboratories University of Turku Turku Finland.
Lassi LuomalaDepartment of Urology University of Helsinki and Helsinki University Hospital Helsinki Finland.ORCID https://orcid.org/0000-0003-0053-7302
Tuomas MirttiResearch Program in Systems Oncology, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0003-0455-9891
Kalle MattilaComprehensive Cancer Center Helsinki University Hospital Helsinki Finland.
Paula VainioDepartment of Pathology Turku University Hospital Turku Finland.
Maria SundvallDepartment of Oncology and Radiotherapy, FICAN West Cancer Centre University of Turku and Turku University Hospital Turku Finland.ORCID https://orcid.org/0000-0002-0494-2965
Panu M JaakkolaDepartment of Oncology and Radiotherapy, FICAN West Cancer Centre University of Turku and Turku University Hospital Turku Finland.ORCID https://orcid.org/0000-0002-2365-4985

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate nuclear promyelocytic leukaemia protein (PML) expression as a prognostic biomarker in localised clear cell renal cell carcinoma (ccRCC), aiming to improve postoperative risk stratification. Materials and methods: Two independent retrospective cohorts of patients undergoing surgery for localised ccRCC were analysed: an exploratory cohort ( Results: High nuclear PML expression was associated with improved RFS ( Conclusions: Nuclear PML expression is associated with favourable outcomes in localised ccRCC and may provide additional prognostic information. Independent validation and mechanistic studies are warranted.

Indexed as

cancer‐specific survivalclear cell renal cell carcinomaimmunohistochemistryoverall survivalprognostic biomarkerpromyelocytic leukaemia proteinrecurrence

Identifiers

PMID42540407
PMCPMC13426025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.